|
1
|
Di Bernardo A, Macor P, Guarnotta C, et
al: Humoral immunotherapy of multiple myeloma: perspectives and
perplexities. Exp Opin Biol Ther. 10:863–873. 2010.PubMed/NCBI
|
|
2
|
Palumbo A and Mina R: Management of older
adults with multiple myeloma. Blood Rev. 27:133–142. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dalton WS: Drug resistance and drug
development in multiple myeloma. Semin Oncol. 29:21–25. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bommert K, Bargou RC and Stuhmer T:
Signalling and survival pathways in multiple myeloma. Eur J Cancer.
42:1574–1580. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ni H, Ergin M, Huang Q, et al: Analysis of
expression of nuclear factor kappa B (NF-kappa B) in multiple
myeloma: downregulation of NF-kappa B induces apoptosis. Br J
Haematol. 115:279–286. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wolverton T and Lalande M: Identification
and characterization of three members of a novel subclass of
protocadherins. Genomics. 76:66–72. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bertrand KC, Mack SC, Northcott PA, et al:
PCDH10 is a candidate tumour suppressor gene in medulloblastoma.
Childs Nerv Syst. 27:1243–1249. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li Y, Yang ZS, Song JJ, Liu Q and Chen JB:
Protocadherin-10 is involved in angiogenesis and methylation
correlated with multiple myeloma. Int J Mol Med. 29:704–710.
2012.PubMed/NCBI
|
|
9
|
Li Z, Li W, Xie J, et al: Epigenetic
inactivation of PCDH10 in human prostate cancer cell lines. Cell
Biol Int. 35:671–676. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li Z, Xie J, Li W, et al: Identification
and characterization of human PCDH10 gene promoter. Gene.
475:49–56. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ma JG, He ZK, Ma JH, Li WP and Sun G:
Downregulation of protocadherin-10 expression correlates with
malignant behaviour and poor prognosis in human bladder cancer. J
Int Med Res. 41:38–47. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Narayan G, Scotto L, Neelakantan V, et al:
Protocadherin PCDH10, involved in tumor progression, is a frequent
and early target of promoter hypermethylation in cervical cancer.
Genes Chromosomes Cancer. 48:983–992. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang KH, Liu HW, Lin SR, Ding DC and Chu
TY: Field methylation silencing of the protocadherin 10 gene in
cervical carcinogenesis as a potential specific diagnostic test
from cervical scrapings. Cancer Sci. 100:2175–2180. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ying J, Gao Z, Li H, et al: Frequent
epigenetic silencing of protocadherin 10 by methylation in multiple
haematologic malignancies. Br J Haematol. 136:829–832. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ying J, Li H, Seng TJ, et al: Functional
epigenetics identifies a protocadherin PCDH10 as a candidate tumor
suppressor for nasopharyngeal, esophageal and multiple other
carcinomas with frequent methylation. Oncogene. 25:1070–1080. 2006.
View Article : Google Scholar
|
|
16
|
Yu B, Yang H, Zhang C, et al:
High-resolution melting analysis of PCDH10 methylation levels in
gastric, colorectal and pancreatic cancers. Neoplasma. 57:247–252.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yu J, Cheng YY, Tao Q, et al: Methylation
of protocadherin 10, a novel tumor suppressor, is associated with
poor prognosis in patients with gastric cancer. Gastroenterology.
136:640–651.e1. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Moreaux J, Legouffe E, Jourdan E, et al:
BAFF and APRIL protect myeloma cells from apoptosis induced by
interleukin 6 deprivation and dexamethasone. Blood. 103:3148–3157.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tai YT, Li XF, Breitkreutz I, et al: Role
of B-cell-activating factor in adhesion and growth of human
multiple myeloma cells in the bone marrow microenvironment. Cancer
Res. 66:6675–6682. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Aggarwal BB: Nuclear factor-kappaB: the
enemy within. Cancer Cell. 6:203–208. 2004.PubMed/NCBI
|
|
21
|
Bharti AC, Shishodia S, Reuben JM, et al:
Nuclear factor-kappaB and STAT3 are constitutively active in
CD138+ cells derived from multiple myeloma patients, and
suppression of these transcription factors leads to apoptosis.
Blood. 103:3175–3184. 2004.PubMed/NCBI
|
|
22
|
Hideshima T, Chauhan D, Richardson P, et
al: NF-kappa B as a therapeutic target in multiple myeloma. J Biol
Chem. 277:16639–16647. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li ZW, Chen H, Campbell RA, Bonavida B and
Berenson JR: NF-kappaB in the pathogenesis and treatment of
multiple myeloma. Curr Opin Hematol. 15:391–399. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hu Y, Sun CY, Huang J, Hong L, Zhang L and
Chu ZB: Antimyeloma effects of resveratrol through inhibition of
angiogenesis. Chin Med J. 120:1672–1677. 2007.PubMed/NCBI
|
|
25
|
Sun CY, Hu Y, Guo T, et al: Resveratrol as
a novel agent for treatment of multiple myeloma with matrix
metalloproteinase inhibitory activity. Acta Pharmacol Sin.
27:1447–1452. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sun C, Hu Y, Liu X, et al: Resveratrol
downregulates the constitutional activation of nuclear
factor-kappaB in multiple myeloma cells, leading to suppression of
proliferation and invasion, arrest of cell cycle, and induction of
apoptosis. Cancer Genet Cytogenet. 165:9–19. 2006. View Article : Google Scholar
|
|
27
|
Fernandes-Alnemri T, Litwack G and Alnemri
ES: CPP32, a novel human apoptotic protein with homology to
Caenorhabditis elegans cell death protein Ced-3 and
mammalian interleukin-1 beta-converting enzyme. J Biol Chem.
269:30761–30764. 1994.PubMed/NCBI
|
|
28
|
Deveraux QL and Reed JC: IAP family
proteins - suppressors of apoptosis. Genes Dev. 13:239–252. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gross A, McDonnell JM and Korsmeyer SJ:
BCL-2 family members and the mitochondria in apoptosis. Genes Dev.
13:1899–1911. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pahl HL: Activators and target genes of
Rel/NF-kappaB transcription factors. Oncogene. 18:6853–6866. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shimizu H, Mitomo K, Watanabe T, Okamoto S
and Yamamoto K: Involvement of a NF-kappa B-like transcription
factor in the activation of the interleukin-6 gene by inflammatory
lymphokines. Mol Cell Biol. 10:561–568. 1990.PubMed/NCBI
|
|
32
|
Shishodia S and Aggarwal BB: Nuclear
factor-kappaB activation: a question of life or death. J Biochem
Mol Biol. 35:28–40. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zandi E, Rothwarf DM, Delhase M, Hayakawa
M and Karin M: The IkappaB kinase complex (IKK) contains two kinase
subunits, IKKalpha and IKKbeta, necessary for IkappaB
phosphorylation and NF-kappaB activation. Cell. 91:243–252. 1997.
View Article : Google Scholar : PubMed/NCBI
|
